

R&D and Medical Affairs

Eckart Holtz, MSc

Vice president R&D and Medical Affairs



Disclaimer:

THIS PRESENTATION HAS BEEN PREPARED BY PRONOVA BIOPHARMA ASA (THE "COMPANY") EXCLUSIVELY FOR INFORMATION PURPOSES. THIS PRESENTATION HAS NOT BEEN REVIEWED OR REGISTERED WITH ANY PUBLIC AUTHORITY OR STOCK EXCHANGE. THE DISTRIBUTION OF THIS PRESENTATION AND ANY OFFERING, SUBSCRIPTION, PURCHASE OR SALE OF SECURITIES ISSUED BY THE COMPANY IN CERTAIN JURISDICTIONS IS RESTRICTED BY LAW. POTENTIAL INVESTORS ARE REQUIRED BY THE COMPANY TO INFORM THEMSELVES ABOUT AND TO COMPLY WITH ALL APPLICABLE LAWS AND REGULATIONS IN FORCE IN ANY JURISDICTION IN WHICH IT INVESTS AND MUST OBTAIN ANY CONSENT, APPROVAL OR PERMISSION REQUIRED UNDER THE LAWS AND REGULATIONS IN FORCE IN SUCH JURISDICTION. THE COMPANY SHALL NOT HAVE ANY RESPONSIBILITY OR LIABILITY FOR THESE OBLIGATIONS. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY JURISDICTION TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH AN OFFER OR SOLICITATION IN SUCH JURISDICTION.


Mature & diverse pipeline with clear R&D strategy

	Indications	Pre-clinical	Phase I	Phase II	Phase III	Market
Monotherapy						
Omacor/Lovaza	HTG	→	→	→	→	→
	Post MI	→	→	→	→	→
	Atrial fibrillation	→	→	→	→	
	Heart failure	→	→	→	→	
	Primary prevention of cardiovascular disease (Diabetes type II)	→	→	→	→	
New formulations (bioequivalence)						
Omacor + Simvastatin ¹	Dyslipidemia				→	
Capsule technology ²					→	
New products						
PRB programmes	Cardiovascular	→				
	Metabolic	→				
	Chronic inflammation	→				

¹ Fixed combination expected to be in clinical trials in 2008


² Alginate capsule expected to be in clinical trials in 2010

Our business model



Focused biopharma model leveraging Pronova BioPharma's core strengths

R&D process



Research and development:

Investment into future growth

- **Strong market position**

- *With Omacor/Lovaza, and a short/medium term program with new formulations, combination products and new clinical indications*

- **High level of internal technical expertise**

- *In the fatty acid field*
- *Chemistry, biology and medical*

- **Growing international patent portfolio**


- *Covering fatty acid derivatives and chemical process development*

- **R&D organisation build-up**

R&D organisation

- **Focused, lean and growing team with strong external focus**
- **People expertise**
 - *PhDs, MD, MSc, in pharmacy, organic chemistry, biochemistry, biology, pharmacology, toxicology*
- **Drug discovery and development experience**
 - *AstraZeneca, GE Healthcare, Pfizer, others*
 - *University research*

R&D and medical affairs organisation



Next ...



Sum-up:

R&D highlights

- **Discovery projects:**

- *Chemical synthesis program on-going*
- *Broadening of our in vitro screening capabilities at CRO's and academic institutions*
- *Key studies on model compounds in progress in in- vivo test systems of metabolic disorders*
- *Goal to identify alternatives as candidates for preclinical development by the end of 2008*

- **Early development:**

- *PRB-2 finished major preclinical safety toxicology studies with the bioanalytical follow-up and additional studies on-going*
- *Evaluation of chemical process optimisation has started*
- *Decision on further development steps and clinical program design by the end of 2008 including collaboration partnering*

Pronova R&D Strategy


- **Global R&D network with strong relationships to academia, CROs and our partners**
- **Development of omega-3 lipid derived pharmaceuticals focused on:**
 - *Cardiovascular;*
 - *Metabolic diseases and*
 - *Chronic inflammation disease areas*
- **Internal expertise in chemical synthesis, process optimization, industrial up-scaling**
- **Aim to have a new drug candidate every two years**
- **Strong IPR in strategic business areas**



**Pronova BioPharma at the forefront
of omega-3 and lipid derived product development**

Patent portfolio for new lipid candidates

- **Patent portfolio supports future lipid drug candidates**
 - *within the Cardiovascular/Metabolic program and/or Chronic inflammation program.*
- **20 patent families**
 - *10 were acquired*



Note: Patents numbers on the graphs do not sum to total patent count due to summary nature of the graphs (e.g., Europe may have patents in separate countries, US provisional patent applications need to be followed up by US regular or forging filings)

Pronova's Early Stage Pipeline

Program	Product pipeline	Target	Indication	Drug discovery		Early development	
				Lead identification	Lead optimisation	Preclinical development	Phase 1
Cardiovascular and metabolic programme	PRB-2	PPAR modulator	Mixed dyslipidemia Diabetes type II	→			
	Discovery project	PPAR modulators	Mixed dyslipidemia Diabetes type II	→			
	Discovery project	Undisclosed	HTG Mixed dyslipidemia	→			
	Discovery project	Novel targets		→			
Chronic inflammation programme	Discovery project	NHR modulators	Chronic inflammation	→			
	Discovery project	Novel targets	Chronic inflammation	→			